ZEJULA® (niraparib) - Maintenance Treatment for Recurrent Ovarian Cancer

The information on this page pertains to the maintenance therapy indication for ZEJULA.

With ZEJULA, You Have a Choice About What Comes Next in Your Ovarian Cancer Treatment

ZEJULA is a once-daily, oral medicine used for the maintenance treatment of women with recurrent ovarian, fallopian tube, or primary peritoneal cancer when their cancer comes back.

ZEJULA is the first and only once-daily PARP inhibitor used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.1-3
See below for full Indication.

Connect With Women Who Are Sharing Their Experiences

You may have questions about ZEJULA. Some who've been there may have answers and inspiring stories. Watch the videos below or visit the Connect With Others page to register for a free live event in your area today.

Video thumbnail: Watch Anne's ovarian cancer story

ANNE | BRCA* status unknown

Staying Grateful With Anne
After being diagnosed with ovarian cancer, Anne learned the true meaning of gratitude. Watch her story.

Video thumbnail: Watch Debi's ovarian cancer story

DEBI | BRCA-positive

Living Large With Debi
Debi has always had a taste for adventure. Learn how living with ovarian cancer has motivated her to continue making the most of each day.


ZEJULA My Way is a patient support program filled with information, guidance, and tools you can use as you take an active role in your treatment.

Sign up today


Commercial Co-pay
Assistance Program

Our Commercial Co-pay Assistance program may reduce your co-pay and/or coinsurance to as little as $0 with a $26,000 annual maximum if you have commercial insurance


ZEJULA offered nearly


time in response to chemotherapy for women with an inherited BRCA mutation vs watch and wait (placebo)1,4

See the data

ZEJULA offered


time in response to chemotherapy for women without an inherited BRCA mutation vs watch and wait (placebo)1,4

See the data

ZEJULA was evaluated as a maintenance treatment in a double-blind, placebo-controlled phase 3 trial of 553 women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who‡1

  • Received at least 2 platinum-based chemotherapy treatments, and
  • Had a complete or partial response to the most recent chemotherapy

The study was designed to measure how long women lived with epithelial ovarian, fallopian tube, or primary peritoneal cancer without their disease getting worse. The treatment benefit of ZEJULA was independently tested in women with an inherited BRCA mutation and without an inherited BRCA mutation.1

Ovarian Cancer

Get more information about what ovarian cancer recurrence might mean for you

Understand Recurrent Ovarian Cancer

Increased Time
in Response

Learn how ZEJULA may extend your time in response


During Treatment

Find resources that may help you access and pay for ZEJULA

Get Access and Support

*BRCA stands for breast cancer susceptibility gene. BRCA refers to particular genes that produce proteins that suppress tumors. BRCA proteins help repair damaged DNA in cells. You may hear the terms BRCA1 and BRCA2 proteins. Mutations in BRCA may mean that it no longer functions. A BRCA gene mutation can be inherited from a parent. When this happens, it is known as a germline BRCA (gBRCA) mutation. When there is a mutation in BRCA that is not passed from a parent to a child, it is called a somatic BRCA (sBRCA) mutation.

This means a change (also called a mutation) has been noted in the BRCA gene. A positive result does not mean that cancer will occur, but this puts you at a higher risk for certain cancers.

65 women who were BRCA-positive received a placebo (eg, sugar pill), and 116 women who were BRCA-negative received a placebo.

Back to Top